Smart Im­mune picks up $5M from Gates Foun­da­tion; Ox­ford Nanopore teams up with French di­ag­nos­tics play­er

French biotech Smart Im­mune has been hand­ed an eq­ui­ty in­vest­ment of $5 mil­lion from the Bill & Melin­da Gates Foun­da­tion.

The cash will specif­i­cal­ly go to ad­vanc­ing a new Phase I/II clin­i­cal tri­al for Smart Im­mune’s lead as­set, called SMART 101. The drug can­di­date will be used in pa­tients with acute leukemia, with the even­tu­al goal of de­vel­op­ing and re­leas­ing an HIV-re­sis­tant cell ther­a­py prod­uct.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER